Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...

Viral Hepatitis I: Introduction

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

Chronic Bowel Disorders: Introduction

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Regional Comparisons of the Prevalence and Socioeconomics of Hepatitis Delta Virus in Two Southern California Counties.

Journal of viral hepatitis·2026

Same author

Serum Proteomic Profile Based on the TGF-β Pathway Stratifies Risk of Hepatocellular Carcinoma.

Liver international : official journal of the International Association for the Study of the Liver·2025

Same author

Natural History of Indeterminate Liver Nodules in Patients With Advanced Liver Disease: A Multicenter Retrospective Cohort Study.

The American journal of gastroenterology·2024

Same author

Nontraditional Treatment of Hepatic Encephalopathy.

Clinics in liver disease·2024

Same author

Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses.

JHEP reports : innovation in hepatology·2024

Same author

Leveraging a community-based participatory approach to improve linkage to care for HBV.

Clinical liver disease·2023

Same journal

Opportunities and Risks of Host-targeting Antiviral Strategies for Hepatitis C.

Current hepatitis reports·2020

Same journal

Managing Hepatitis C in Users of Illicit Drugs.

Current hepatitis reports·2013

Same journal

Alcoholic Hepatitis: Steroids vs. Pentoxifylline.

Current hepatitis reports·2013

Same journal

DILI: New Insights into Diagnosis and Management.

Current hepatitis reports·2013

Same journal

Primary Sclerosing Cholangitis: Current and Future Management Strategies.

Current hepatitis reports·2013

Same journal

Optimal Management of the Hepatitis B Patient Who Desires Pregnancy or Is Pregnant.

Current hepatitis reports·2012

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 1, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Combination Therapy for Chronic Hepatitis B: Current Indications.

Navin Paul, Steven-Huy Han

Current Hepatitis Reports

|June 10, 2011

Summary

This summary is machine-generated.

Hepatitis B treatment is evolving. Combination therapy, inspired by HIV treatment, is being studied for its effectiveness and safety in managing chronic Hepatitis B infection.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Related Experiment Videos

Last Updated: Jun 1, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Area of Science:

Hepatology
Virology
Public Health

Background:

Hepatitis B infection is a significant global health issue.
Available treatments target viral and host factors.
HIV treatment success inspired Hepatitis B combination therapy research.

Purpose of the Study:

To review the current role of combination therapy for chronic Hepatitis B.
To analyze the efficacy and safety of drug combinations.

Main Methods:

Literature review of existing studies.
Analysis of therapeutic agents and treatment options.
Evaluation of combination therapy strategies.

Main Results:

Combination therapy shows promise in managing Hepatitis B.
Efficacy and safety data for various drug combinations are under investigation.
The review synthesizes current evidence on combination approaches.

Conclusions:

Combination therapy is a key area of research for chronic Hepatitis B.
Further studies are needed to optimize treatment regimens.
This approach may improve patient outcomes and resource utilization.